Literature DB >> 12905144

Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study.

Jesús Canueto-Quintero1, Francisco Javier Caballero-Granado, Marta Herrero-Romero, Angel Domínguez-Castellano, Patricia Martín-Rico, Elisa Vidal Verdú, Daniel Selma Santamaría, Ricardo Creagh Cerquera, Manuel Torres-Tortosa.   

Abstract

A multicenter, comparative study was performed to determine the epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium tuberculosis and Mycobacterium kansasii in human immunodeficiency virus (HIV)-infected patients. From 1 January 1995 through 31 December 1999, 25 HIV-infected patients received diagnoses of M. kansasii infection, and another 75 were selected as control subjects from among patients who had M. tuberculosis infection. Variables associated with M. tuberculosis disease in the multivariate analysis were previous intravenous drug use (odds ratio [OR], 8; 95% confidence interval [CI], 1.5-41.4) and interstitial radiologic pattern (OR, 12.7; 95% CI, 1.7-94.3). Variables associated with M. kansasii were previous diagnosis of acquired immunodeficiency syndrome (OR, 15.8; 95% CI, 4.2-59.6) and concomitant opportunistic infections (OR, 14.2; 95% CI, 2-105.7). Clinical and radiologic features were similar for both groups, but epidemiological characteristics and prognosis were different. M. kansasii disease was associated more closely with level of immunosuppression and progression of HIV infection than was disease caused by M. tuberculosis.

Entities:  

Mesh:

Year:  2003        PMID: 12905144     DOI: 10.1086/376987

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.

Authors:  Fernando Alcaide; Laura Calatayud; Miguel Santín; Rogelio Martín
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Cutaneous Manifestations of Mycobacterium kansasii Infection.

Authors:  L Hojat; F Tobolowsky; C Franco-Paredes
Journal:  Curr Trop Med Rep       Date:  2018-08-06

Review 3.  Other HIV-associated pneumonias.

Authors:  Jakrapun Pupaibool; Andrew H Limper
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

4.  Isolated Mycobacterium kansasii wound infection and Osteomyelitis in an immunocompetent patient.

Authors:  Tarek Turk; Mohamed Faher Almahmoud; Khulood Raslan
Journal:  Oxf Med Case Reports       Date:  2016-11-04

5.  Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii.

Authors:  Joyce Wang; Fiona McIntosh; Nicolas Radomski; Ken Dewar; Roxane Simeone; Jost Enninga; Roland Brosch; Eduardo P Rocha; Frédéric J Veyrier; Marcel A Behr
Journal:  Genome Biol Evol       Date:  2015-02-25       Impact factor: 3.416

6.  Therapy for Mycobacterium kansasii Infection: Beyond 2018.

Authors:  Michelle S DeStefano; Carolyn M Shoen; Michael H Cynamon
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640

Review 7.  Mycobacterial Evolution Intersects With Host Tolerance.

Authors:  Joseph W Saelens; Gopinath Viswanathan; David M Tobin
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.